PepGen (PEPG) Surges 90% on DM1 Trial Data

PepGen shares jumped about 90% after its DM1 drug PGN-EDODM1 delivered 46.5% mean splicing correction in a Phase 2 trial, the highest in multi-dose studies.

Lead

What Did PepGen Report?

PepGen reported mean splicing correction of 46.5% at the 10 mg/kg dose, against 6.8% in the placebo group. Splicing correction measures how far the drug repairs the faulty RNA processing that drives myotonic dystrophy type 1, a muscle-wasting genetic disease. Four of six treated patients exceeded 50% correction, and the company described the result as the highest reported in a multiple-dose DM1 study.

Functional measures moved in the same direction at Week 16:

• Video hand opening time, a measure of myotonia (delayed muscle relaxation), improved by 3.9 seconds, or about 52.7%, versus 0.2 seconds for placebo.
• Hand grip strength improved by about 16.2%.
• The Timed Up and Go test improved by 8.5%, and the 10-meter walk/run test by 6.8%.

Adverse events were mild to moderate. Nausea was the most frequent. A transient rise in urinary protein followed the first dose, with no sign of cumulative kidney damage over the 16-week observation period.

Why Did PepGen Shares Nearly Double?

Shares nearly doubled because the splicing figure sets a new benchmark in a competitive field. Dyne Therapeutics (DYN) previously reported 25% mean splicing correction in a Phase 1/2 trial, and PepGen's number is close to double that. Guggenheim Securities analysts called the data potentially the new benchmark for splicing.

The reaction also reflects the stock's starting point. PepGen entered the session as a small-cap developer with a partial regulatory hold. Clean efficacy data and a benign safety profile reset expectations for its lead asset.

What Does the FDA Hold Mean for PepGen?

The partial clinical hold, imposed Mar. 4, 2026, blocks U.S. enrollment in FREEDOM2 but does not stop dosing elsewhere. The FDA cited questions about preclinical pharmacology and toxicology data, particularly renal findings in animal studies. The 10 mg/kg cohort was enrolled entirely outside the United States, at sites in Canada, the U.K., New Zealand, Australia and South Korea.

No timeline for lifting the hold has been given. The absence of kidney signals in the human data supports the company's case, but resolution rests with the agency. Until it is lifted, American patients cannot take part and any pivotal program would depend on non-U.S. enrollment.

Financial Position

PepGen held $117.2 million in cash and marketable securities as of June 30, 2026. Management guides to funding into the fourth quarter of 2027. That runway covers the next data readouts but likely not a late-stage trial, so a capital raise is a standard next step for a company after a share price move of this size.

What Comes Next for PepGen?

Three milestones follow. Interim open-label extension safety data at 5 mg/kg and 10 mg/kg is expected in January 2027. Results from the 12.5 mg/kg cohort are due in the first half of 2027. After that, PepGen is expected to decide on pivotal trial design and open discussions with the FDA on the hold.

The trial is small, with six treated patients at the reported dose. Durability and dose response will determine whether the 46.5% figure holds up. Investors tracking the wider biotech etf segment will also watch whether the result lifts sentiment toward other RNA-targeted neuromuscular developers.

Outlook

PepGen's rally rests on one dataset, but it is the strongest splicing result yet reported in DM1 and arrives with a clean early safety profile. The next test is January's safety update, then the higher-dose cohort in the first half of 2027. The FDA hold and a funding runway that ends in late 2027 remain the main constraints on the company's path to a pivotal study.